Back to Search
Start Over
Tailored hyaluronic acid-based nanogels as theranostic boron delivery systems for boron neutron cancer therapy.
- Source :
-
International journal of pharmaceutics: X [Int J Pharm X] 2022 Oct 14; Vol. 4, pp. 100134. Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Boron-rich nanocarriers possess great potential for advanced boron neutron capture therapy (BNCT) as an effective radiation treatment for invasive malignant tumors. If additionally, they can be imaged in a non-invasive and real-time manner allowing the assessment of local boron concentration, they could serve for dose calculation and image-guided BNCT to enhance tumor treatment efficacy. To meet this challenge, this study describes the design of a theranostic nanogel, enriched in <superscript>10</superscript> B and fluorescent dye, to achieve selective imaging, and sufficient accumulation of boron at the tumor site. The boron-rich and fluorescent nanogels can be easily obtained via temperature triggered-assembly of hyaluronic acid (HA) modified with a thermoresponsive terpolymer. The latter was specifically designed to enable the efficient encapsulation of the fluorescent dye - an aza‑boron-dipyrromethene (aza-BODIPY) - linked to <superscript>10</superscript> B-enriched sodium borocaptate (BSH), in addition to induce nanogel formation below room temperature, and to enable their core-crosslinking by hydrazone bond formation. The HA nanogel considerably concentrates aza-BODIPY-BSH into the hydrophobic nanodomains made of the terpolymer chains. Here, we present the detailed synthesis of the HA-terpolymer conjugate, nanogel formation, and characterization in terms of size, morphology, and stability upon storage, as well as the biological behavior of the boron nanocarrier using real-time fluorescence imaging in cells and in vivo. This work suggested the potential of the theranostic HA nanogel as a boron delivery system for the implementation of BNCT in brain cancer and sarcoma.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2022 The Authors.)
Details
- Language :
- English
- ISSN :
- 2590-1567
- Volume :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of pharmaceutics: X
- Publication Type :
- Academic Journal
- Accession number :
- 36304136
- Full Text :
- https://doi.org/10.1016/j.ijpx.2022.100134